Marker Therapeutics Inc (MRKR)

[4fatcat4]

TPIV 100/200, MultiTAAs, PolyStart! All of these treatments have proven to be safe and non-invasive, effective, inexpensive, in varying degrees. All of this was known prior to the pancreatic fiasco, yet we still find ourselves mired with a share price under 4.

To this point the science appears solid, meaning moving forward MRKR would appear to greatly enhance current vaccine and tumor treatments. TPIV's vaccine treatment already has orphan and fast track designations, while MultiTAAs and Polystart surely qualify as such.

Now you'd think ANYONE doing their DD on MRKR would jump at the chance to invest in a company with these assets, much less with a market price of 200m. Look at their advisory board, administration and the science itself, it all appears very impressive.

So tell me again why the hell we're at 4, can't be all the shorters fault, can it?